Due to these results, particularly its high tumor accumulation at 1 h p.i., [18F]F-[natLu]Lu-DOTA-rhCCK-18 could surpass the detection rate of currently applied CCK-2R-targeted compounds such as [111In]In-CP04 or [68Ga]Ga-DOTA-MGS5 [9,28,34,35] and might even compete with the current gold standard for MTC imaging, [18F]F-DOPA, i.e., for the detection of distant metastases. The gene discussed is CCKBR; the disease is medullary thyroid gland carcinoma.